Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael Dolsten, MD, PhD, joins Typewriter board as independent director and the Fred Hutch’s Stanley R. Riddell, MD, joins Typewriter Scientific Advisory Board